SCHEMBL1750080

SCHEMBL1750080

CC(C)(C)[Si](OC1CCC2(CC1)CCN(Cc1c(Cl)cc(-c3ccc(F)cc3)cc1Cl)C2=O)(c1ccccc1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.41
RIPK1 Q13546 2/20 0.36
DRD2 P14416 5/20 0.34
SIGMAR1 Q99720 3/20 0.34
CCR3 P51677 1/20 0.34
OPRM1 P35372 1/20 0.33
OPRK1 P41145 1/20 0.33
OPRL1 P41146 1/20 0.33
EGLN1 Q9GZT9 3/20 0.32
HDAC11 Q96DB2 2/20 0.31
HSD11B1 P28845 1/20 0.31
DRD4 P21917 1/20 0.31
DRD3 P35462 1/20 0.31
HCRTR1 O43613 2/20 0.31
HCRTR2 O43614 2/20 0.31
HTR1A P08908 1/20 0.31
HTR7 P34969 1/20 0.31
SLC16A3 O15427 1/20 0.31
SLC16A1 P53985 1/20 0.31
MCTS1 Q9ULC4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1750496 0.90 BACE1 (0.40) BACE1RIPK1EGLN1HDAC11
SCHEMBL1752202 0.88 BACE1 (0.39) BACE1RIPK1HDAC11HCRTR1HCRTR2
SCHEMBL1750366 0.87 BACE1 (0.40) BACE1RIPK1HDAC11HCRTR1HCRTR2
SCHEMBL1751913 0.85 RIPK1 (0.39) BACE1RIPK1
SCHEMBL1750766 0.84 BACE1 (0.37) BACE1RIPK1DRD2CCR3HDAC11
SCHEMBL1750955 0.84 BACE1 (0.38) BACE1HCRTR1HCRTR2
SCHEMBL1750995 0.78 RIPK1 (0.41) RIPK1CCR3HDAC11HSD11B1
SCHEMBL1750994 0.78 RIPK1 (0.41) RIPK1CCR3HDAC11HSD11B1
SCHEMBL1750890 0.76 RIPK1 (0.40) RIPK1CCR3HDAC11HCRTR1HCRTR2
SCHEMBL18208407 0.74 BACE1 (0.41) BACE1EGLN1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968585-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2011-06-28 US disclosed
EP-2035379-B1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2010-06-16 EP disclosed
US-20090099180-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-16 US disclosed
EP-2035379-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 Eli Lilly & Company (US) 2009-03-18 EP disclosed
WO-2007127763-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099180-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD11B2, HSD3B1 BACE1 155/4885RIPK1 2806/4885DRD2 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.